Why this drug is interesting
Icatibant is a good test of how a clinician handles mechanistic reasoning. The argument for using it in ACE-inhibitor angioedema is genuinely attractive: ACE breaks down bradykinin, ACE inhibition raises bradykinin, bradykinin acting at the B2 receptor produces the swelling, and icatibant blocks that receptor. Every step is true.
The conclusion still did not survive contact with a randomised trial. That gap — between a mechanism that is correct and a benefit that is absent — is the most instructive thing about this drug, and it recurs across emergency medicine far more often than it is taught.
Pharmacology
Mechanism
Icatibant is a synthetic decapeptide and a selective competitive antagonist at the bradykinin type 2 (B2) receptor.1 It contains five non-proteinogenic amino acids, which is what makes it resistant to the peptidases that would otherwise destroy it — and is why it can be given subcutaneously with predictable absorption.
In hereditary angioedema, C1-esterase-inhibitor deficiency permits unchecked activation of the contact system, generating bradykinin. Bradykinin acting at B2 receptors on vascular endothelium increases permeability, producing the characteristic non-pitting, non-urticarial, non-pruritic swelling. Blocking the receptor addresses the final common mediator rather than the upstream deficiency.
Kinetics
- Route
- Subcutaneous — no IV formulation
- Bioavailability
- ~97% subcutaneously
- Terminal half-life
- About 1–2 hours
- Metabolism
- Extensive peptidase metabolism to inactive metabolites
- Excretion
- Metabolites in urine; less than 10% of dose as unchanged drug
No dose adjustment is needed for renal or hepatic impairment, and the kinetics are unaffected by age enough to require adjustment in adults — a useful simplicity in a drug given during a crisis.
Indications and dosing
The licensed indication is symptomatic treatment of acute attacks of hereditary angioedema in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.1
Adults
- 30 mg by subcutaneous injection, preferably into the abdominal area
- If response is inadequate or symptoms recur, a second injection after 6 hours
- If still inadequate, a third injection after a further 6 hours
- No more than 3 injections in any 24-hour period
Children and adolescents aged 2–17 years
| Body weight | Dose | Volume |
|---|---|---|
| 12–25 kg | 10 mg | 1.0 mL |
| 26–40 kg | 15 mg | 1.5 mL |
| 41–50 kg | 20 mg | 2.0 mL |
| 51–65 kg | 25 mg | 2.5 mL |
| Over 65 kg | 30 mg | 3.0 mL |
Self-administration
Many HAE patients carry their own supply and may have self-injected before arrival. Establish what has already been given and when — it directly determines whether a further dose is permissible within the three-in-24-hours ceiling.
The ACE-inhibitor angioedema question
ACE-inhibitor-induced angioedema is far more common in the ED than hereditary angioedema, and it is also bradykinin-mediated. The mechanistic case for icatibant is therefore strong, and early small studies were encouraging.
Two randomised controlled trials published in 2017 tested it properly.
| Trial | Design | Result |
|---|---|---|
| Straka et al.3 | Single-centre, double-blind, placebo-controlled; 33 patients (13 icatibant, 18 placebo) | No statistically significant difference in time to symptom resolution |
| CAMEO — Sinert et al.4 | International multicentre, double-blind, placebo-controlled; 121 randomised (~60 icatibant, ~58 placebo) | Icatibant no more efficacious than placebo in shortening time to meeting discharge criteria |
Reading the trials fairly
- Both trials are modest in size; neither definitively excludes a small benefit, and CAMEO was powered for a clinically meaningful difference rather than any difference at all.
- In CAMEO, over 90% of participants had already received corticosteroids, antihistamines or adrenaline before enrolment — so the comparison is icatibant-plus-usual-care against usual-care, not against nothing.
- Enrolment necessarily favoured patients stable enough to consent and randomise, so the sickest airways are under-represented — the group in whom clinicians most want an answer.
- None of this rescues the hypothesis. Two independent negative trials is the best evidence available, and practice should follow it rather than the mechanism.
The honest summary is that the mechanism was right and the drug still did not help, probably because by the time a patient presents, the swelling is established and its resolution is governed by processes a receptor antagonist arrives too late to influence.
Contraindications, cautions and adverse effects
Contraindications
Hypersensitivity to icatibant or any excipient. That is the entire list — unusually short, and a point in the drug's favour.
Cautions
- Acute ischaemic heart disease or unstable angina — caution is advised; bradykinin has vasodilator and possibly cardioprotective roles, and blocking B2 receptors could theoretically worsen ischaemia
- In the weeks following a stroke — theoretical attenuation of bradykinin's neuroprotective effects
- Laryngeal attacks require in-hospital observation after injection
Adverse effects
Injection site reactions are very common and largely expected — erythema, swelling, burning, itch and pain at the abdominal site, typically mild and self-limiting. Beyond that the profile is quiet: headache, dizziness, nausea, rash and a transient rise in transaminases are reported.
Practical use in the ED
Recognising which angioedema you are treating
| Feature | Histaminergic | Bradykinin-mediated (HAE / ACE-I) |
|---|---|---|
| Urticaria and itch | Usually present | Absent |
| Onset | Minutes | Hours, evolving over 24–36 h |
| Response to adrenaline/antihistamine/steroid | Good | Poor or absent |
| Trigger | Allergen exposure | Often none identifiable; ACE-I may have been taken for years |
| Family history | Not typical | Common in HAE |
Where HAE is confirmed, C1-esterase inhibitor concentrate is an alternative first-line agent depending on local immunology protocols; know which your trust stocks and where it is kept, because both agents are held in restricted locations and the delay is usually in finding them, not in giving them.
Critical appraisal
- The HAE evidence base is small but coherent, and rests on placebo- and comparator-controlled trials in a rare disease where large studies are not feasible. Judged against what is achievable in that population, it is reasonable evidence.
- The ACE-inhibitor story is a cautionary tale about mechanism. A biologically compelling rationale, promising early data, then two independent negative randomised trials. Practice should follow the trials.
- Cost and access shape real-world use more than most monographs admit. Icatibant is expensive and often held centrally, which means the practical question in a district general ED at 3am is frequently not whether it is indicated but whether it can be obtained in a useful timeframe.
- No amount of pharmacology substitutes for airway planning. The deaths in angioedema are airway deaths. A monograph that leaves a reader more confident about drug selection than about when to call for a surgical airway has done harm rather than good.
References
- 1Icatibant 30 mg solution for injection in pre-filled syringe — Summary of Product Characteristics. electronic Medicines Compendium. Sections 4.1–4.4, 5.1–5.2. Verified 20 Aug 2026. Note the originator brand Firazyr is listed on emc as discontinued; generic icatibant SmPCs carry the current UK labelling.
- 2Icatibant — dosing and safety monograph. BNF, NICE. bnf.nice.org.uk
- 3Straka BT, Ramirez CE, Byrd JB, et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol 2017;140(1):242–48. PubMed
- 4Sinert R, Levy P, Bernstein JA, et al. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor–induced upper airway angioedema (CAMEO). J Allergy Clin Immunol Pract 2017;5(5):1402–09. Journal30172-1/fulltext)
- 5Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor–induced angioedema. N Engl J Med 2015;372(5):418–25. NEJM (the earlier positive small trial, superseded by refs 3 and 4).
- 6Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema — 2021 revision and update. Allergy 2022;77(7):1961–90.